Gritstone Bio Operating Margin 2017-2024 | GRTSQ
Current and historical operating margin for Gritstone Bio (GRTSQ) over the last 10 years. The current operating profit margin for Gritstone Bio as of June 30, 2024 is -910.50%.
Gritstone Bio Operating Margin Historical Data |
Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
2024-06-30 |
$0.02B |
$-0.14B |
-913.33% |
2024-03-31 |
$0.02B |
$-0.15B |
-906.25% |
2023-12-31 |
$0.02B |
$-0.14B |
-875.00% |
2023-09-30 |
$0.01B |
$-0.14B |
-1420.00% |
2023-06-30 |
$0.01B |
$-0.13B |
-1209.09% |
2023-03-31 |
$0.01B |
$-0.13B |
-907.14% |
2022-12-31 |
$0.02B |
$-0.12B |
-636.84% |
2022-09-30 |
$0.02B |
$-0.12B |
-661.11% |
2022-06-30 |
$0.02B |
$-0.12B |
-650.00% |
2022-03-31 |
$0.02B |
$-0.11B |
-700.00% |
2021-12-31 |
$0.05B |
$-0.08B |
-153.06% |
2021-09-30 |
$0.05B |
$-0.07B |
-153.19% |
2021-06-30 |
$0.05B |
$-0.07B |
-155.56% |
2021-03-31 |
$0.04B |
$-0.07B |
-169.05% |
2020-12-31 |
$0.00B |
$-0.11B |
-3533.33% |
2020-09-30 |
$0.00B |
$-0.11B |
-3566.67% |
2020-06-30 |
$0.00B |
$-0.11B |
-3633.33% |
2020-03-31 |
$0.00B |
$-0.11B |
-2625.00% |
2019-12-31 |
$0.00B |
$-0.10B |
-2425.00% |
2019-09-30 |
$0.00B |
$-0.09B |
-2175.00% |
2019-06-30 |
$0.00B |
$-0.08B |
-2600.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|